Fundamental Data for PTIE

Pain Therapeutics is developing a new generation of opioid painkillers.Opioids are drugs derived from the poppy plant. The company uses technology to reformulate opioid drugs, such as morphine, into new painkillers with improved clinical benefits. The company has four opioid painkillers in Phase II clinical trials. The company believes its drugs offer enhanced pain relief, fewer adverse side effects and reduced tolerance and addiction compared to existing opioid painkillers.

# Employees: 48

Address: 2211 Bridgepointe Parkway Suite 500,San Mateo,CA,USA

Phone: 650 624-8200

Fax: 650 624-8222

Website: www.paintrials.com

Email: investor-relations@paintrials.com

Sector: Medical

Industry: MED-DRUGS

Executive Officers

Remi Barbier (Chmn.; Presi.; C.E.O.)

Peter S. Roddy (V.P.; C.F.O.)

Nadav Friedmann M.D. (Chief Opera. & Medical Off.; Dir.)

Michael J. O'Donnell Esq. (Sec.; Dir.)

Robert Z. Gussin Ph.D. (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/4/2010

Mean EPS (Next Qtr): ($0.04)

Mean EPS (Year): ($0.13)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 3

Shares Performance

Period	PTIE	Compare to S&P
YTD	-19.76 %	-33.60 %
4 Weeks	-12.20 %	-13.15 %
12 Weeks	-7.95 %	-13.21 %

Shares Information

Analyst Coverage: Y

Avg Volume: 204663

Shares Outstanding: 42M

Market Cap: $0.20B

52 Week High: $8.78

52 Week Low: $3.34

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 PTIE split by factor of 2.500

Earnings Performance

EPS Growth in Last Quarter: -0.01 %

EPS Growth in Last Year: -108.57 %

Sales Growth in Last Quarter: -39.66 %

Sales Growth in Last Quarter: -87.58 %

Financials

Qtr Book Value: $1.89

Cash Flow/Share: $12.63

Change in Payout Ratio: -0.010

Price/Sales: 7.990